Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension

Study Purpose

This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria for WHO Group 2. 1. 18 years or older. 2. Symptomatic WHO Functional Class (FC)

III. 3.

Based on preexisting echocardiography within the past 6 months, evidence of right heart dysfunction: RV ejection fraction (RVEF) < 45% by visual estimate, and at least one of the following: 1. Tricuspid Annulus Plane Systolic Excursion (TAPSE) ≤16 mm. 2. RV Fractional area change <35% 3. RVs' velocity < 10 cm/s. 4. RV free wall strain <18% 5. RVEF < 35% by visual estimate. 4. MPA diameter > 32mm and length >70 mm as determined by preexisting fluoroscopy, echocardiography, computerized tomography, or magnetic resonance imaging within the past 6 months. 5. Elevated pulmonary arterial pressure based on preexisting resting RHC within the past 6 months: Mean PAP (mPAP) > 30 mmHg. 6. Intra-procedural confirmation of elevated pulmonary arterial pressure based on resting RHC: mPAP > 30 mmHg. 7. Patient is willing and able to provide informed consent. 8. Previous diagnosis of left heart dysfunction. 9. Intra-procedural confirmation of WHO Group 2 diagnosis based on resting RHC: 1. PAWP: >15 and ≤30 mmHg, and. 2. Combined post- and pre-capillary pulmonary hypertension (CpcPH), defined as PVR > 3 WU. Exclusion Criteria for WHO Group 2. 1. Anatomy not suitable for RHC. 2. Anatomy not suitable for placement of Aria CV Acute Device: 1. Contraindication to 16 Fr femoral vein access. 2. Body habitus that would preclude safe placement of any components of Aria CV Acute Device. 3. Any previous tricuspid valvular surgery, percutaneous valve repair, or presence of prosthetic cardiac device such as pacemaker or defibrillator leads, or vena cava filter that in the opinion of the investigator may interfere with investigational device placement or performance. 4. Uncontrolled atrial fibrillation. 5. Sustained tachyarrhythmia (heart rate >110/min) at time of index procedure. 6. Right heart valve regurgitation: 1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation. 2. Severe (Grade 4) tricuspid valve regurgitation. 7. Patient with any of the following medical history or comorbidities: 1. History of unprovoked Pulmonary Embolism or CTEPH. 2. Currently on dialysis. 3. Current or recent (<6 months prior to planned index procedure) endocarditis. 4. Clinically significant patent foramen ovale or other inter-atrial or inter-ventricular shunt. 5. Current active systemic infection requiring antibiotic therapy. 8. As determined by the physician the subject is medically unstable and/or represents an unreasonable procedural risk. 9. Hypersensitivity or contraindication to. 1. Required medications (e.g. contrast agents, heparin) which cannot be adequately managed, or. 2. Materials in investigational device including polyurethane, silicone, nickel, and titanium. 10. Pregnant or lactating woman. 11. Currently participating in other investigational drug or device trials that may interfere with the outcome of this study. 12. Diagnosis of WHO Groups 1, 3, 4 or 5 PH. 13. Previous diagnosis of idiopathic hypertrophic subaortic stenosis (IHSS, also known as hypertrophic obstructive cardiomyopathy-HOCM) 14. Untreated aortic or mitral stenosis. Inclusion Criteria for WHO Group 3. 1. 18 years or older. 2. Symptomatic WHO Functional Class (FC)

III. 3.

Based on preexisting echocardiography within the past 6 months, evidence of right heart dysfunction: RV ejection fraction (RVEF) < 45% by visual estimate, and at least one of the following: 1. Tricuspid Annulus Plane Systolic Excursion (TAPSE) ≤16 mm. 2. RV Fractional area change <35% 3. RVs' velocity < 10 cm/s. 4. RV free wall strain <18% 5. RVEF < 35% by visual estimate. 4. MPA diameter > 32mm and length >70 mm as determined by preexisting fluoroscopy, echocardiography, computerized tomography, or magnetic resonance imaging within the past 6 months. 5. Elevated pulmonary arterial pressure based on preexisting resting RHC within the past 6 months: Mean PAP (mPAP) > 30 mmHg. 6. Intra-procedural confirmation of elevated pulmonary arterial pressure based on resting RHC: mPAP > 30 mmHg. 7. Patient is willing and able to provide informed consent. 8. Previous diagnosis of chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis. 9. Intra-procedural confirmation of WHO Group 3 diagnosis based on resting RHC: 1. PAWP≤ 15 mmHg, and. 2. PVR > 4 WU. Exclusion Criteria for WHO Group 3. 1. Anatomy not suitable for RHC. 2. Anatomy not suitable for placement of Aria CV Acute Device: 1. Contraindication to 16 Fr femoral vein access. 2. Body habitus that would preclude safe placement of any components of Aria CV Acute device. 3. Any previous tricuspid valvular surgery, percutaneous valve repair, or presence of prosthetic cardiac device such as pacemaker or defibrillator leads, or vena cava filter that in the opinion of the investigator may interfere with investigational device placement or performance. 4. Uncontrolled atrial fibrillation. 5. Sustained tachyarrhythmia (heart rate >110/min) at time of index procedure. 6. Right heart valve regurgitation: 1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation. 2. Severe (Grade 4) tricuspid valve regurgitation. 7. Patient with any of the following medical history or comorbidities: 1. History of unprovoked Pulmonary Embolism or CTEPH. 2. Currently on dialysis. 3. Current or recent (<6 months prior to planned index procedure) endocarditis. 4. Clinically significant shunt such as patent foramen ovale, inter-atrial or inter-ventricular shunt, or other. 5. Current active systemic infection requiring antibiotic therapy. 8. As determined by the physician the subject is medically unstable and/or represents an unreasonable procedural risk. 9. Hypersensitivity or contraindication to. 1. Required medications (e.g. contrast agents, warfarin, heparin) which cannot be adequately managed, or. 2. Materials in investigational device including polyurethane, silicone, nickel, and titanium. 10. Pregnant or lactating woman. 11. Currently participating in other investigational drug or device trials that may interfere with the outcome of this study. 12. Diagnosis of WHO Groups 1, 2, 4 or 5 PH

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05001711
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	N/A
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Aria CV, Inc
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Irene M Lang, MD
Principal Investigator Affiliation	Medical University of Vienna
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Industry
Overall Status	Recruiting
Countries	Austria
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Pulmonary Hypertension

Additional Details

This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients. The planned enrollment is a maximum enrollment of 40 patients to ensure up to 10 "Device Deployed" subjects in each arm at one site. The duration of study participation for each subject is expected to be approximately 60 days.

Arms & Interventions

Arms

Experimental: WHO Group 2

Experimental: WHO Group 3

Interventions

Device: - Aria CV Acute PH System

The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.